NEW YORK, March 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

http://www.reportlinker.com/p01859471/Pharmaceutical-Industry-in-China---Cutting-Edge-Analysis-of-Multinational-and-Chinese-Pharma-Companies-Industry-Trends-Environment-Regulation-Market-Drivers-Restraints-Opportunities--Challenges.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

"Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages. The Chinese biopharmaceutical market is presented as follows:

• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

• Company financials, sales & revenue figures – historical to Q2•2013• China GDP, economic growth, export (bulk drug, formulations) figures• Indian health expenditure as a function of GDP• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)• Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market• Top Five Contract Pharmaceutical Export Markets of China• Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)• Multinational penetration into the Chinese Pharma Market• Comprehensive product portfolios, R&D activity and pipeline therapeutics • M&A activity and future strategies of top Chinese pharmacos• Economic indicators, trade policy, merchandise and commercial trade statistics• Gross Domestic Product of China, historic and projection analysis• Chinese economic outlook in comparison to advanced economies • Three Tier 'Pharmerging' Markets with Potential for Significant Growth • Prescription drug sales distribution channels in China• Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

• Amoytop Biotech• Active Pharmaceutical Products• Beijing Continent Pharmaceuticals• FusoGen Pharmaceuticals• Shanghai Huaguan Biochip• SiBiono GeneTech• Abbott• AstraZeneca• Boehringer Ingelheim• Eli Lilly• GlaxoSmithKline• Johnson & Johnson Medical• Merck• Novartis• Pfizer• Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

• An in-depth understanding of the Chinese biopharmaceutical market and it's environment

• Current market facts, figures and product lines of key players in the industry

• An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market

• Knowledge of how the Chinese pharma market will integrate into the global healthcare market

• Information on key regulatory and government policies

• Data on levels of private and publically funded biopharma studies in China

• Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

• Lack of regulatory policy and legislation

• Reimbursement schemes and payers concerns

• Funding and government sponsorship issues

• International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

• Strong, competitive players

• Pooling their resources for specific growth and therapeutic areas

• Investing strategically in R&D

• Have a history of strategic M&A activity

1.0 Summary 81.1 Objectives of Report 81.2 Scope of Study 91.3 Data Sources and Methodology 101.4 Key Findings and Observations 101.5 Executive Summary 112.0 Chronic Disease Prevalence Statistics 143.0 Business Environment 163.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 163.2 Gross Domestic Product of China, Historic and Projection Analysis 183.3 Annual Health Expenditure in China, Historic and Projected Analysis 193.4 Global and Chinese Economic Outlook 2010-2013 203.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 213.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 234.0 Chinese Pharmaceutical Market 284.1 Market Overview 284.2 Main Players in China's Pharmaceutical Industry 314.3 Anti-Allergy Drug Market 314.4 Asthma Drug Market 324.5 Benign Prostate Hyperplasia Drug Market 324.6 Anti-Depressant Drug market 334.7 Dermatitis Drug Market 354.8 Diabetes Drug Market 364.9 Hypertension Drug Market 374.10 Dyslipidaemia Drug Market 384.11 Senile Dementia Drug Market 394.12 Cancer Drug Market 404.13 Rheumatoid Arthritis Drug Market 404.14 Ophthalmological Drug Market 414.15 Liver Disease Drug Market 434.16 Antibiotic Drug Market 445.0 Government and Regulation Environment 455.1 12th Five Year Plan 455.2 Intellectual Property for Pharmaceuticals in China 475.3 State Food and Drug Administration (SFDA) 525.4 Pharmaceutical Distribution Process in China 556.0 China – Third Largest Pharma Market 2012 586.1 China – At the Forefront of Emerging Markets 586.2 Generic Medication Market and China 586.3 Novel Product Drug Development 606.4 Drug Development Cost and Outsourcing 626.5 Drug Development Case Study - Beijing Continent Pharmaceuticals 636.6 China's Pharmaceutical Export Market 636.7 Spot Light - China Medical City Taizhou 657.0 Global Pharmaceutical Companies Interest in China 677.1 Abbott China 677.2 AstraZeneca China 767.3 Bayer China 847.4 Boehringer Ingelheim China 887.5 Eli Lilly China 927.6 GlaxoSmithKline China 947.7 Johnson & Johnson Medical China 997.8 Merck China 1047.9 Novartis China 1077.10 Novo Nordisk China 1117.11 Pfizer China 1147.11.1 Pfizer China R&D Centre 1167.11.2 Pfizer China Products 1167.11.3 Pfizer Financials 1197.11.4 Pfizer Global 1207.12 Roche China 1217.13 Sanofi China 1278.0 Chinese Pharmaceutical Companies 1318.1 Amoytop Biotech 1318.2 Active Pharmaceutical Products 1338.2.1 Research and Development 1348.2.2 Financial Information 1348.3 Beijing Continent Pharmaceuticals 1348.4 FusoGen Pharmaceuticals 1358.4.1 Financial Information 1368.5 Shanghai Huaguan Biochip 1368.5.1 Financial Information 1398.6 SiBiono GeneTech 1398.6.1 Financial Information 1408.7 Sinovac Biotech 1408.7.1 Financial Information 1428.7.2 New Products 1478.7.3 Split Virion Pandemic Influenza Vaccine 1478.7.4 RabEnd 1478.7.5 Pipeline Portfolio 1478.7.6 EV71 virus Vaccine 1478.7.7 Pneumococcal Conjugate Vaccine 1488.7.8 Pneumococcal Polysaccharide Vaccine 1488.7.9 Varicella Vaccine 1488.7.10 Measles, Mumps and Rubella Vaccines 1488.7.11 Rotavirus Vaccine 1489.0 Drivers, Restraints, Challenges and Opportunity Analysis 1499.1 Key Drivers of the Pharmaceutical Market in China 1499.2 Key Restraints of the Pharmaceutical Market in China 1509.3 Challenges of the Pharmaceutical Industry in China 1519.4 Opportunities Within BioPharma China 153

List of Tables

Table 2.1: Most Prominent Cancer Manifestations in China 15Table 2.2: Top Fifty Diseases in China Today (non-cancer) 15Table 2.3: Top Infectious Disease States in China Today 15Table 3.1: World Trade Organisation Basic Indicators on China 16Table 3.2: World Trade Organisation Trade Policy of China 16Table 3.3: World Trade Organisation Merchandise Trade Statistics: China 17Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China 17Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China 18Table 3.6: China Statistics 18Table 4.1: Top Global Pharma Markets 2003-2013 28Table 4.2: Major Players in China's Anti-Allergy Drug Market 31Table 4.3: Major Players in China's Asthma Drug Market 32Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market 33Table 4.5: Major Players in China's Anti-Depressant Drug Market 34Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 35Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 35Table 4.8: Major Players in China's Dermatitis Drug Market 35Table 4.9: Major Players in China's Diabetic Drug Market 37Table 4.10: Major Players in China's Hypertension Drug Market 38Table 4.11: Major Players in China's Dyslipidaemia Drug Market 38Table 4.12: Major Players in China's Senile Dementia Drug Market 39Table 4.13: Major Players in China's Cancer Drug Market 40Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market 41Table 4.15: Major Players in China's Ophthalmological Drug Market 42Table 4.16: Major Players in China's Liver Disease Drug Market 43Table 4.17: Major Players in China's Antibiotic Drug Market 44Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015 45Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012 47Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China 55Table 5.4: Prescription Drug Sales Distribution Channels in China 55Table 6.1: Major Biogeneric Products in China 59Table 6.2: Imported Therapeutics with Administrative Protection in China 59Table 6.3: Expired Proprietary Pharmaceuticals in China 60Table 6.4: Reasons Why Multinational Companies Seek CMO's in China 62Table 6.5: Comparison of Clinical Trial Cost between China and the USA 63Table 6.6: Five Functional Districts of China Medical City 65Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City 66Table 7.1: Top Multinational Company Performance, China 67Table 7.2: Abbott Areas of Expertise 69Table 7.3: Abbott Key Global Products 72Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions 72Table 7.5: Abbott China Anaesthesia Product Profile 72Table 7.6: Abbott China Cardiovascular Product Profile 72Table 7.7: Abbott China Vaccine Product Profile 73Table 7.8: Abbott China Digestion Product Profile 73Table 7.9: Abbott China HIV Product Profile 73Table 7.10: Abbott Rheumatology HIV Product Profile 73Table 7.11 Abbott China Gynaecological Product Profile 73Table 7.12 Abbott China Urological Product Profile 73Table 7.13 Abbott China Liver Disease Product Profile 73Table 7.14 Abbott China Diagnostic Product Profile 73Table 7.15: Abbott China Molecular Diagnostic Product Profile 74Table 7.16: Abbott Blood Glucose Meter Product Profile 75Table 7.17: Abbott Cardiovascular Product Profile 75Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile 75Table 7.19: Important Milestones in AstraZeneca China's History 76Table 7.20: AstraZeneca China Anaesthetic Range of Products 77Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products 77Table 7.22: AstraZeneca China Gastrointestinal Range of Products 77Table 7.23: AstraZeneca China Infection Range of Products 77Table 7.24: AstraZeneca China Neurology Range of Products 77Table 7.25: AstraZeneca China Oncology Range of Products 77Table 7.26: AstraZeneca China Respiratory Range of Products 77Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 80Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 80Table 7.29: Bayer China Important Milestones 85Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China 86Table 7.31: Bayer - Leading Therapeutics in China 87Table 7.32: Bayer Top Selling Consumer Health Products 88Table 7.33: Boehringer Ingelheim Major Products in China 88Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China 89Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim 90Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products 91Table 7.37: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 ($ billion) and Percentage Change 93Table 7.38: GlaxoSmithKline Prescription Portfolio and Indications in China 94Table 7.39: GlaxoSmithKline Vaccine Portfolio and Indications in China 95Table 7.40: GlaxoSmithKline Over the Counter Portfolio and Indications in China 95Table 7.41: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2013 97Table 7.42: GlaxoSmithKline Global Vaccine Sales FY2012-2013 98Table 7.43: Significant Milestones in Johnson and Johnson China History 100Table 7.44: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2013 103Table 7.45: Merck Serono Pharmaceutical Key Therapeutic Areas in China 104Table 7.46: Merck Serono Fertility and Infertility Therapeutic Portfolio in China 104Table 7.47: Merck Serono Therapeutic Portfolio in China 105Table 7.48: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 105Table 7.49: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013 105Table 7.50: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013 106Table 7.51: Range of Diabetic Products from Novo Nordisk China 111Table 7.52: QUICKFACTs - Pfizer China 115Table 7.53: Important Milestones – Pfizer China 115Table 7.54: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market 116Table 7.55: Pfizer China – Range of Mental Health Products for Chinese Health Care Market 117Table 7.56: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market 117Table 7.57: Pfizer China – Range of Endocrine Products for Chinese Health Care Market 117Table 7.58: Pfizer China – Range of Women's Health Products for Chinese Health Care Market 117Table 7.59: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market 117Table 7.60: Pfizer China – Range of Oncology Products for Chinese Health Care Market 117Table 7.61: Pfizer – Key Consumer Healthcare Global Products 118Table 7.62: Pfizer – Key Speciality Care Global Products 118Table 7.63: Pfizer – Key Oncology Global Products 118Table 7.64: Pfizer – Key Global Established Products 118Table 7.65: Pfizer – Key Innovative Products in Emerging Markets 118Table 7.66: Pfizer – Key Animal Health Global Products 119Table 7.67: Pfizer Product Sales with Significant Impact on Revenues 2012:2013 Comparison 119Table 7.68: Roche Pharmaceuticals Product List in China 122Table 7.69: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012 & 2013 and Percentage Change (CER) 124Table 7.70: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012, 2013 and Percentage Change (CER) 126Table 7.71: Seven Growth Platforms of Sanofi China 127Table 7.72: Key Therapeutic Areas of Sanofi China 128Table 8.1: Important Milestones in Amoytop Biotech's Development 131Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division 132Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies 132Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China 133Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech 133Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 133Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 136Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals 136Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 137Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile 137Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 137Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 137Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 130Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 139Table 8.15: Gendicine - Potential Oncology Indications for Future Approval 140Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 141Table 8.17: Important Milestones in the History of Sinovac Biotech 141Table 8.18: Pipeline Portfolio of Sinovac Biotech 141Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 144Table 9.1: Key Drivers of the Pharmaceutical Market in China 149Table 9.2: Key Restraints of the Pharmaceutical Market in China 150Table 9.3: Key Challenges of the Pharmaceutical Market in China 151Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020 151Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China 153?

List of Figures

Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages 14

Figure 3.1: China GDP Figures 2006-2015 19

Figure 3.2: Annual Health Expenditure in China 2006-2015 19

Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013 20

Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013 21

Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013 22

Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 22

Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 23

Figure 3.8: Global, US and Germany Economic Growth 2010-2013 24

Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017 24

Figure 3.10: Global, France and Italy Economic Growth 2010-2013 25

Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 25

Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 26

Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 26

Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 27

Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 30

Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 46

Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs 53

Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials 54

Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market 56

Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market 56

Figure 6.1: Three Tier 'Pharmerging' Markets with Potential for Significant Growth 58

Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010 60

Figure 6.3: Number of New Drug Applications in China 2003-2010 61

Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China 61

Figure 6.5: Percentage of Clinical Trial Drug by Disease State 62

Figure 6.6: China's Regional Pharmaceutical Processing Trade Export Market Share Percentage 64

Figure 6.7: Contract Amount of China's Regional Pharmaceutical Processing Trade Export 64

Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 65

Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets 69

Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 70

Figure 7.3: Abbott – Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals 70

Figure 7.4: Abbott Diversified Medical Product Portfolio 71

Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in China, 2010-2013 79

Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, Emerging Markets 2012 79

Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 2010-2012 81

Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012 81

Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012 82

Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012 82

Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012 83

Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012 83

Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development 91

Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2013 (£ Billions) 96

Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012-2013 97

Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012-2013 98

Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, 2012-2013 99

Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2013 103

Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012-2013 109

Figure 7.20: Novartis International Sales (US$ Millions) by Geographic Region, 2012-2013 110

Figure 7.21: Novo Nordisk Total China Sales 2009-2013 113

Figure 7.22: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China 2010-2013 113

Figure 7.23: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2013 114

Figure 7.24: Business Sectors – Pfizer China 116

Figure 7.25: Roche Total Global Sales (CHF Millions) 2012-2013 125

Figure 7.26: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2013 125

Figure 7.27: Roche Pharmaceutical Division Emerging Market Total Sales 2012-2013 126

Figure 7.28: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2012-2013 127

Figure 7.29: Sanofi Geographic Market Share (%) – Emerging Markets, USA and Western Europe 2012 129

Figure 7.30: Sanofi Geographic Market Share (%) –China, Russia and USA 2012 130

Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression 135

Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 138

Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 143

Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012 144

Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 145

Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 145

Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 146

Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 146

To order this report: Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges http://www.reportlinker.com/p01859471/Pharmaceutical-Industry-in-China---Cutting-Edge-Analysis-of-Multinational-and-Chinese-Pharma-Companies-Industry-Trends-Environment-Regulation-Market-Drivers-Restraints-Opportunities--Challenges.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker